AIIMS Director Dr. Guleria gives important information about Covaxin trial
AIIMS Director Dr. Guleria gives important information about Covaxin trial
Share:

New Delhi: Human trial of COVAXIN, the indigenous vaccine of the coronavirus, has started at the All India Institute of Age of Science (AIIMS), Delhi, the country's capital. AIIMS director Dr. Randeep Guleria said on Monday that after the first phase of the corona vaccine, the second phase of AIIMS Delhi trial is going on. It is a dormant virus from which humans have to be protected.

Dr. Randeep Guleria further said that many people have registered to join the trial. So far 1800 volunteers have registered. Healthy people from 18 to 55 years old will be identified for trial. Initially, samples of 1125 healthy people will be taken. In the first phase, 375 people were tried. 100 healthy volunteers will be selected for AIIMS. Phase-II will be tried on volunteers aged 12 to 65.

AIIMS director Guleria said that during the trial of the Corona vaccine, people will be given a lot of doses. The dose of the vaccine will be given in the control situation which is called a placebo. This is a controlled study. Once the vaccine dose is given, volunteers will be monitored to see if there are any side effects of the vaccine. Its data will be prepared by the data monitoring board. If we feel that it is safe, then we will go ahead and increase the quantity of doses.

Also Read-

CM Yogi approves home quarantine on lines of Delhi Government

'Godhan Nyaya Yojana' starts from today, government will buy 'cow dung' from farmers

Corona vaccine trial continues in AIIMS, Patna

Share:
Join NewsTrack Whatsapp group
Related News